PARTICULARITIES OF THE COURSE AND TREATMENT HEMANGIOMAS OF DIFFERENT MORPHOLOGICAL TYPES IN CHILDREN AND THEIR ASSOCIATION WITH SOLUBLE FORMS OF FAS AND FASL
Abstract
The article discusses analysis of examinations and treatment results 100 children with hemangiomas different localizations on the different stages of existence. The study included patients of different ages, from birth to 6 years. Importance of primary assessment of severity and activity of hemangioma`s, for the choice of treatment, was considered. Correlation between clinical course of hemangiomas and soluble Fas/FasL was analyzed.
The object of the research: Clinical course of hemangiomas of different morphological types, soluble form of Fas and FasL in the serum of patients with hemangiomas.
Investigated problem: Improving the results of treatment of hemangiomas in children.
The main scientific results: Predicting the course of hemangiomas in children allows to determine the need for treatment at different stages of their existence, as well as to carry out timely correction of the prescribed treatment to achieve good cosmetic and functional results.
The area of practical use of the research results: Department of Pediatrics, Pediatric Surgery, Dermatology.
Innovative technological product: Defined characteristics will help in predicting the course of hemangiomas and the effectiveness of their treatment.
Scope of the innovative technological product: Clinical pediatric practice.
Downloads
References
Bota, M., Popa, G., Blag, C., Tataru, A. (2015). Infantile hemangioma: a brief review. Medicine and Pharmacy Reports, 88 (1), 23–27. doi: http://doi.org/10.15386/cjmed-381 DOI: https://doi.org/10.15386/cjmed-381
International Society for the Study of Vascular Anomalies (2018). ISSVA classification of vascular anomalies.
Mulligan, P. R., Prajapati, H. J. S., Martin, L. G., Patel, T. H. (2014). Vascular anomalies: classification, imaging characteristics and implications for interventional radiology treatment approaches. The British Journal of Radiology, 87 (1035), 20130392. doi: http://doi.org/10.1259/bjr.20130392 DOI: https://doi.org/10.1259/bjr.20130392
Püttgen, K. B. (2014). Diagnosis and Management of Infantile Hemangiomas. Pediatric Clinics of North America, 61 (2), 383–402. doi: http://doi.org/10.1016/j.pcl.2013.11.010 DOI: https://doi.org/10.1016/j.pcl.2013.11.010
Rotter, A., de Oliveira, Z. N. P. (2017). Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. JDDG: Journal Der Deutschen Dermatologischen Gesellschaft, 15 (12), 1185–1190. doi: http://doi.org/10.1111/ddg.13365 DOI: https://doi.org/10.1111/ddg.13365
Yu, Y., Fuhr, J., Boye, E., Gyorffy, S., Soker, S., Atala, A. et. al. (2006). Mesenchymal Stem Cells and Adipogenesis in Hemangioma Involution. STEM CELLS, 24 (6), 1605–1612. doi: http://doi.org/10.1634/stemcells.2005-0298 DOI: https://doi.org/10.1634/stemcells.2005-0298
Lee, J. W., Chung, H. Y. (2018). Vascular anomalies of the head and neck: current overview. Archives of Craniofacial Surgery, 19 (4), 243–247. doi: http://doi.org/10.7181/acfs.2018.02383 DOI: https://doi.org/10.7181/acfs.2018.02383
Luu, M., Frieden, I. J. (2013). Haemangioma: clinical course, complications and management. British Journal of Dermatology, 169 (1), 20–30. doi: http://doi.org/10.1111/bjd.12436 DOI: https://doi.org/10.1111/bjd.12436
Léauté-Labrèze, C., Harper, J. I., Hoeger, P. H. (2017). Infantile haemangioma. The Lancet, 390 (10089), 85–94. doi: http://doi.org/10.1016/s0140-6736(16)00645-0 DOI: https://doi.org/10.1016/S0140-6736(16)00645-0
Boscolo, E., Bischoff, J. (2009). Vasculogenesis in infantile hemangioma. Angiogenesis, 12 (2), 197–207. doi: http://doi.org/10.1007/s10456-009-9148-2 DOI: https://doi.org/10.1007/s10456-009-9148-2
Ji, Y., Wang, Q., Chen, S., Xiang, B., Xu, Z., Li, Y. et. al. (2016). Oral atenolol therapy for proliferating infantile hemangioma. Medicine, 95 (24), e3908. doi: http://doi.org/10.1097/md.0000000000003908 DOI: https://doi.org/10.1097/MD.0000000000003908
Garzon, M. C., Epstein, L. G., Heyer, G. L., Frommelt, P. C., Orbach, D. B., Baylis, A. L. et. al. (2016). PHACE Syndrome: Consensus-Derived Diagnosis and Care Recommendations. The Journal of Pediatrics, 178, 24–33.e2. doi: http://doi.org/10.1016/j.jpeds.2016.07.054 DOI: https://doi.org/10.1016/j.jpeds.2016.07.054
Gontijo, B. (2014). Complications of infantile hemangiomas. Clinics in Dermatology, 32 (4), 471–476. doi: http://doi.org/10.1016/j.clindermatol.2014.02.002 DOI: https://doi.org/10.1016/j.clindermatol.2014.02.002
Satterfield, K. R., Chambers, C. B. (2019). Current treatment and management of infantile hemangiomas. Survey of Ophthalmology, 64 (5), 608–618. doi: http://doi.org/10.1016/j.survophthal.2019.02.005 DOI: https://doi.org/10.1016/j.survophthal.2019.02.005
Darrow, D. H., Greene, A. K., Mancini, A. J., Nopper, A. J. (2015). Diagnosis and Management of Infantile Hemangioma. Pediatrics, 136 (4), e1060–e1104. doi: http://doi.org/10.1542/peds.2015-2485 DOI: https://doi.org/10.1542/peds.2015-2485
Pu ttgen, K., Lucky, A., Adams, D., Pope, E., McCuaig, C. et. al. (2016). Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics, 138 (3), e20160355. doi: http://doi.org/10.1542/peds.2016-0355 DOI: https://doi.org/10.1542/peds.2016-0355
Zhang, L., Yuan, W.-E., Zheng, J.-W. (2016). Pharmacological therapies for infantile hemangiomas: A clinical study in 853 consecutive patients using a standard treatment algorithm. Scientific Reports, 6 (1). doi: http://doi.org/10.1038/srep21670 DOI: https://doi.org/10.1038/srep21670
Koka, K., Mukherjee, B., Agarkar, S. (2018). Effect of oral propranolol on periocular Capillary Hemangiomas of Infancy. Pediatrics & Neonatology, 59 (4), 390–396. doi: http://doi.org/10.1016/j.pedneo.2017.11.021 DOI: https://doi.org/10.1016/j.pedneo.2017.11.021
Leaute-Labreze, C., Boccara, O., Degrugillier-Chopinet, C., Mazereeuw-Hautier, J., Prey, S., Lebbe, G. et. al. (2016). Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. Pediatrics, 138 (4), e20160353. doi: http://doi.org/10.1542/peds.2016-0353 DOI: https://doi.org/10.1542/peds.2016-0353
Harter, N., Mancini, A. J. (2019). Diagnosis and Management of Infantile Hemangiomas in the Neonate. Pediatric Clinics of North America, 66 (2), 437–459. doi: http://doi.org/10.1016/j.pcl.2018.12.011 DOI: https://doi.org/10.1016/j.pcl.2018.12.011
Chen, Z.-Y., Wang, Q.-N., Zhu, Y.-H., Zhou, L.-Y., Xu, T., He, Z.-Y., Yang, Y. (2019). Progress in the treatment of infantile hemangioma. Annals of Translational Medicine, 7 (22), 692–692. doi: http://doi.org/10.21037/atm.2019.10.47 DOI: https://doi.org/10.21037/atm.2019.10.47
Berkman, N. D., Brownley, K. A., Peat, C. M., Cullen, K. E. (2015). Evidence-based practice center systematic review protocol. Project title: Management and outcomes of binge eating disorder (BED).
Grzesik, P., Wu, J. (2017). Current perspectives on the optimal management of infantile hemangioma. Pediatric Health, Medicine and Therapeutics, 8, 107–116. doi: http://doi.org/10.2147/phmt.s115528 DOI: https://doi.org/10.2147/PHMT.S115528
Moyakine, A. V., Herwegen, B., van der Vleuten, C. J. M. (2017). Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas. Journal of the American Academy of Dermatology, 77 (5), 868–873. doi: http://doi.org/10.1016/j.jaad.2017.06.003 DOI: https://doi.org/10.1016/j.jaad.2017.06.003
Smith, C. J. F., Friedlander, S. F., Guma, M., Kavanaugh, A., Chambers, C. D. (2017). Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. Birth Defects Research, 109 (11), 809–815. doi: http://doi.org/10.1002/bdr2.1023 DOI: https://doi.org/10.1002/bdr2.1023
Razon, M. J., Kraeling, B. M., Mulliken, J. B., Bischoff, J. (1998). Increased Apoptosis Coincides with Onset of Involution in Infantile Hemangioma. Microcirculation, 5 (2‐3), 189–195. doi: http://doi.org/10.1111/j.1549-8719.1998.tb00068.x DOI: https://doi.org/10.1111/j.1549-8719.1998.tb00068.x
Xia, P., Gamble, J. R., Rye, K.-A., Wang, L., Hii, C. S. T., Cockerill, P. et. al. (1998). Tumor necrosis factor- induces adhesion molecule expression through the sphingosine kinase pathway. Proceedings of the National Academy of Sciences, 95 (24), 14196–14201. doi: http://doi.org/10.1073/pnas.95.24.14196 DOI: https://doi.org/10.1073/pnas.95.24.14196
Musiał, K., Zwolińska, D. (2011). Matrix metalloproteinases and soluble Fas/FasL system as novel regulators of apoptosis in children and young adults on chronic dialysis. Apoptosis, 16 (7), 653–659. doi: http://doi.org/10.1007/s10495-011-0604-2 DOI: https://doi.org/10.1007/s10495-011-0604-2
Adly, A. A., Ismail, E. A., Andrawes, N. G., Mahmoud, M. M., Eladawy, R. (2016). Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease. Cytokine, 79, 52–58. doi: http://doi.org/10.1016/j.cyto.2015.12.022 DOI: https://doi.org/10.1016/j.cyto.2015.12.022
Luo, J., Wang, Y., Yu, B., Qian, H., He, Y., Shi, G. (2017). A Potential of sFasL in Preventing Gland Injury in Sjogren’s Syndrome. BioMed Research International, 2017, 1–6. doi: http://doi.org/10.1155/2017/5981432 DOI: https://doi.org/10.1155/2017/5981432
Yamada, A., Arakaki, R., Saito, M., Kudo, Y., Ishimaru, N. (2017). Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance. Frontiers in Immunology, 8. doi: http://doi.org/10.3389/fimmu.2017.00403 DOI: https://doi.org/10.3389/fimmu.2017.00403
Izawa, T., Arakaki, R., Ishimaru, N. (2017). Role of Fas and RANKL Signaling in Peripheral Immune Tolerance. Journal of Clinical & Cellular Immunology, 8 (4). doi: http://doi.org/10.4172/2155-9899.1000512 DOI: https://doi.org/10.4172/2155-9899.1000512
Kosacka, M., Porębska, I., Korzeniewska, A., Rubinsztajn, R., Grabicki, M., Jankowska, R. et. al. (2016). Serum levels of apoptosis-related markers (sFasL, TNF-a, p53 and bcl-2) in COPD patients. Pneumonologia i Alergologia Polska, 84 (1), 11–15. doi: http://doi.org/10.5603/piap.a2015.0080 DOI: https://doi.org/10.5603/PiAP.a2015.0080
Zheng, J. W., Zhang, L., Zhou, Q., Mai, H. M., Wang, Y. A., Fan, X. D. et. al. (2013). A practical guide to treatment of infantile hemangiomas of the head and neck. International journal of clinical and experimental medicine, 6 (10), 851–860.
Krowchuk, D. P., Frieden, I. J., Mancini, A. J., Darrow, D. H., Blei, F. et. al. (2018). Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics, 143 (1), e20183475. doi: http://doi.org/10.1542/peds.2018-3475 DOI: https://doi.org/10.1542/peds.2018-3475
Wu, H. W., Liu, C., Wang, X., Zhang, L., Yuan, W., Zheng, J. W. et. al. (2017). Topical Application of 0.5 % Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma. Frontiers in Oncology, 7. doi: http://doi.org/10.3389/fonc.2017.00137 DOI: https://doi.org/10.3389/fonc.2017.00137
Marey, H. M., Elmazar, H. F., Mandour, S. S., Khairy, H. A. (2017). Combined Oral and Topical Beta Blockers for the Treatment of Early Proliferative Superficial Periocular Infantile Capillary Hemangioma. Journal of Pediatric Ophthalmology & Strabismus, 55 (1), 37–42. doi: http://doi.org/10.3928/01913913-20170703-12 DOI: https://doi.org/10.3928/01913913-20170703-12
Dou, T. M. (2017). The evaluation value of the quantitative electroencephalogram for the prognosis of neonatal hypoxic ischemic encephalopathy and its relationship with serological indicators. Journal of Hainan Medical University, 23 (11), 120–123.
Fathi, M., Amirghofran, Z., Shahriari, M. (2011). Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Medical Oncology, 29 (3), 2046–2052. doi: http://doi.org/10.1007/s12032-011-9965-1 DOI: https://doi.org/10.1007/s12032-011-9965-1
Xing, X., Ouyang, T. X., Yuan, S. M. et. al. (2006) The expression and role of Fas/FasL in infantile hemangioma. Chinese Journal of Plastic Surgery, 22 (2), 116–120.
Copyright (c) 2020 Viktoriia Vivcharuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
